On January 14, 2015, Cytori Therapeutics, Inc. will host an information session about advances in scleroderma research and the company’s STAR pivotal trial for its own experimental Scleroderma therapy. This session will take place between 1:30 p.m. and 4:30 p.m. at the Prescott Hotel, 545 Post Street, San Francisco, Room 736, where Dr. Dinesh Khanna, the Cytori’s head researcher in scleroderma, will present on the company’s latest developments.
The STAR pivotal trial, which will begin in 2015, will evaluate Cytori Cell Therapy™ and its ability to serve as a viable treatment for impaired hand function, which impacts the majority of scleroderma patients. Scleroderma is a very rare autoimmune condition that affects almost 50,000 people in the U.S.
The information session offer helpful insights into scleroderma’s epidemiology, as well as current information on how Cytori’s clinical trial will be planned, important data about the company’s lead product, insights into the Scleroderma market opportunity regarding the disease.
Dr. Khanna, who is certified in rheumatology, authored more than 160 publications and book chapters and has received several distinctions for his work, such as the 2007 Spirit of Leadership Award and the 2011 “Best Doctor of the Year” award from the Scleroderma Foundation. Currently, his work is being funded by the National Institutes of Health (NIH). Khanna has also previously worked on designing and leading international clinical trials and evaluating patients’ outcomes regarding scleroderma. Most notably, he was elected by his colleagues to the 2011-2012 Best Doctors in America list.
Cytori Therapeutics is advancing autologous cell therapies from adipose tissue that could be used to treat several health conditions. Cytori Cell Therapy™ works by ameliorating blood flow, regulating the body’s immune system, and promoting wound repair.